Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), filed a Form 4 on September 4, 2026, disclosing the exercise of stock options and sale of 18,500 shares of Class A Common Stock on September 2, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Fordyce exercised stock options covering 18,500 shares of Class A Common Stock at an exercise price of $2.8968 per share on September 2, 2026.
  • Shares sold: 18,500 shares were sold on September 2, 2026, at a weighted-average price of $35.1158, with individual transactions ranging from $35.00 to $35.34 per share.
  • Remaining direct ownership: Following the transactions, Fordyce directly held 235,244 shares of Class A Common Stock.
  • Derivative securities remaining: Fordyce retains 507,301 stock options (right to buy) with an exercise price of $2.8968, expiring December 15, 2030.
  • 10b5-1 plan: According to the filing, the sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c).
  • Option vesting: The filing states that 1/4 of the shares subject to the option vested on December 16, 2021, with 1/48 of the shares vesting monthly thereafter.

Vera Therapeutics CEO Option Exercise and Share Sale Details

According to the Form 4 filed with the SEC, Marshall Fordyce, who serves as President and CEO and is also identified as a Director of Vera Therapeutics, Inc. (NASDAQ:VERA), executed two transactions on September 2, 2026. First, Fordyce acquired 18,500 shares of Class A Common Stock through the exercise of stock options at a conversion price of $2.8968 per share, bringing his directly held shares to 253,744. Second, he disposed of those same 18,500 shares, reducing his direct holdings to 235,244 shares.

The filing reports the sale price as a weighted-average of $35.1158 per share, reflecting multiple transactions conducted at prices ranging from $35.00 to $35.34, inclusive. The filing notes that Fordyce will provide full details of shares sold at each separate price upon request to the SEC staff, the issuer, or any security holder. The transactions were carried out under a written trading plan adopted on January 9, 2026, which the filing states was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

In Table II of the filing, Fordyce is reported to beneficially own 507,301 stock options with an exercise price of $2.8968 per share and an expiration date of December 15, 2030. The Form 4 was signed by Joseph R. Young as Attorney-in-Fact on September 4, 2026. The filing is made by one reporting person and indicates direct ownership for all disclosed positions.

What Was Disclosed

The filing discloses a same-day option exercise and share sale by Vera Therapeutics' President and CEO on September 2, 2026, executed under a pre-established 10b5-1 plan, with the CEO retaining 235,244 directly held shares and 507,301 unexercised stock options following the transactions.